UCB: Data is the New Drug

UCB: Data is the New Drug Description

At the end of 2012, the chief information officer (CIO) at UCB, a global pharmaceutical company based in Brussels, started to implement analytics as a service. Between 2012 and 2016, he put this vision into practice, introducing agile sprints and proving the competence of analytics within the organization, and at the beginning of 2016, he felt the company was ready to upgrade its analytics capability. As he prepared to meet with UCB's chief executive officer in March 2016, the CIO considered how to advise the board as the organization worked to make an impact with analytics and big data against the backdrop of digital turbulence in its strategic environment. How could UCB balance empowerment and bottom-up experimentation with enterprise focus and control? What was the best location for analytics roles and responsibilities within the organization? Stijn Viaene is affiliated with Vlerick Business School.

Case Description UCB: Data is the New Drug

Strategic Managment Tools Used in Case Study Analysis of UCB: Data is the New Drug

STEP 1. Problem Identification in UCB: Data is the New Drug case study

STEP 2. External Environment Analysis - PESTEL / PEST / STEP Analysis of UCB: Data is the New Drug case study

STEP 3. Industry Specific / Porter Five Forces Analysis of UCB: Data is the New Drug case study

STEP 4. Evaluating Alternatives / SWOT Analysis of UCB: Data is the New Drug case study

STEP 5. Porter Value Chain Analysis / VRIO / VRIN Analysis UCB: Data is the New Drug case study

STEP 6. Recommendations UCB: Data is the New Drug case study

STEP 7. Basis of Recommendations for UCB: Data is the New Drug case study

Case Analysis of UCB: Data is the New Drug

UCB: Data is the New Drug is a Harvard Business (HBR) Case Study on Technology & Operations , Texas Business School provides HBR case study assignment help for just $9. Texas Business School(TBS) case study solution is based on HBR Case Study Method framework, TBS expertise & global insights. UCB: Data is the New Drug is designed and drafted in a manner to allow the HBR case study reader to analyze a real-world problem by putting reader into the position of the decision maker. UCB: Data is the New Drug case study will help professionals, MBA, EMBA, and leaders to develop a broad and clear understanding of casecategory challenges. UCB: Data is the New Drug will also provide insight into areas such as – wordlist , strategy, leadership, sales and marketing, and negotiations.

Case Study Solutions Background Work

UCB: Data is the New Drug case study solution is focused on solving the strategic and operational challenges the protagonist of the case is facing. The challenges involve – evaluation of strategic options, key role of Technology & Operations, leadership qualities of the protagonist, and dynamics of the external environment. The challenge in front of the protagonist, of UCB: Data is the New Drug, is to not only build a competitive position of the organization but also to sustain it over a period of time.

Strategic Management Tools Used in Case Study Solution

The UCB: Data is the New Drug case study solution requires the MBA, EMBA, executive, professional to have a deep understanding of various strategic management tools such as SWOT Analysis, PESTEL Analysis / PEST Analysis / STEP Analysis, Porter Five Forces Analysis, Go To Market Strategy, BCG Matrix Analysis, Porter Value Chain Analysis, Ansoff Matrix Analysis, VRIO / VRIN and Marketing Mix Analysis.

Texas Business School Approach to Technology & Operations Solutions

In the Texas Business School, UCB: Data is the New Drug case study solution – following strategic tools are used - SWOT Analysis, PESTEL Analysis / PEST Analysis / STEP Analysis, Porter Five Forces Analysis, Go To Market Strategy, BCG Matrix Analysis, Porter Value Chain Analysis, Ansoff Matrix Analysis, VRIO / VRIN and Marketing Mix Analysis.

We have additionally used the concept of supply chain management and leadership framework to build a comprehensive case study solution for the case – UCB: Data is the New Drug

Step 1 – Problem Identification of UCB: Data is the New Drug - Harvard Business School Case Study

The first step to solve HBR UCB: Data is the New Drug case study solution is to identify the problem present in the case. The problem statement of the case is provided in the beginning of the case where the protagonist is contemplating various options in the face of numerous challenges that Ucb Analytics is facing right now. Even though the problem statement is essentially – “Technology & Operations” challenge but it has impacted by others factors such as communication in the organization, uncertainty in the external environment, leadership in Ucb Analytics, style of leadership and organization structure, marketing and sales, organizational behavior, strategy, internal politics, stakeholders priorities and more.

Step 2 – External Environment Analysis

Texas Business School approach of case study analysis – Conclusion, Reasons, Evidences - provides a framework to analyze every HBR case study. It requires conducting robust external environmental analysis to decipher evidences for the reasons presented in the UCB: Data is the New Drug.

The external environment analysis of UCB: Data is the New Drug will ensure that we are keeping a tab on the macro-environment factors that are directly and indirectly impacting the business of the firm.

What is PESTEL Analysis? Briefly Explained

PESTEL stands for political, economic, social, technological, environmental and legal factors that impact the external environment of firm in UCB: Data is the New Drug case study. PESTEL analysis of " UCB: Data is the New Drug" can help us understand why the organization is performing badly, what are the factors in the external environment that are impacting the performance of the organization, and how the organization can either manage or mitigate the impact of these external factors.

How to do PESTEL / PEST / STEP Analysis? What are the components of PESTEL Analysis?

As mentioned above PESTEL Analysis has six elements – political, economic, social, technological, environmental, and legal. All the six elements are explained in context with UCB: Data is the New Drug macro-environment and how it impacts the businesses of the firm.

How to do PESTEL Analysis for UCB: Data is the New Drug

To do comprehensive PESTEL analysis of case study – UCB: Data is the New Drug , we have researched numerous components under the six factors of PESTEL analysis.

Political Factors that Impact UCB: Data is the New Drug

Political factors impact seven key decision making areas – economic environment, socio-cultural environment, rate of innovation & investment in research & development, environmental laws, legal requirements, and acceptance of new technologies.

Policy Making Impact on UCB: Data is the New Drug

Government policies have significant impact on the business environment of any country. The firm in “ UCB: Data is the New Drug ” needs to navigate these policy decisions to create either an edge for itself or reduce the negative impact of the policy as far as possible.

Data safety laws – The countries in which Ucb Analytics is operating, firms are required to store customer data within the premises of the country. Ucb Analytics needs to restructure its IT policies to accommodate these changes. In the EU countries, firms are required to make special provision for privacy issues and other laws.

Competition Regulations – Numerous countries have strong competition laws both regarding the monopoly conditions and day to day fair business practices. UCB: Data is the New Drug has numerous instances where the competition regulations aspects can be scrutinized.

Import restrictions on products – Before entering the new market, Ucb Analytics in case study UCB: Data is the New Drug" should look into the import restrictions that may be present in the prospective market.

Export restrictions on products – Apart from direct product export restrictions in field of technology and agriculture, a number of countries also have capital controls. Ucb Analytics in case study “ UCB: Data is the New Drug ” should look into these export restrictions policies.

Foreign Direct Investment Policies – Government policies favors local companies over international policies, Ucb Analytics in case study “ UCB: Data is the New Drug ” should understand in minute details regarding the Foreign Direct Investment policies of the prospective market.

Taxation & Regulation Impact on UCB: Data is the New Drug

Corporate Taxes – The rate of taxes is often used by governments to lure foreign direct investments or increase domestic investment in a certain sector. Corporate taxation can be divided into two categories – taxes on profits and taxes on operations. Taxes on profits number is important for companies that already have a sustainable business model, while taxes on operations is far more significant for companies that are looking to set up new plants or operations.

Tariffs – Chekout how much tariffs the firm needs to pay in the “ UCB: Data is the New Drug ” case study. The level of tariffs will determine the viability of the business model that the firm is contemplating. If the tariffs are high then it will be extremely difficult to compete with the local competitors. But if the tariffs are between 5-10% then Ucb Analytics can compete against other competitors.

Government Scheme & Subsidies Impact on UCB: Data is the New Drug

Research and Development Subsidies and Policies – Governments often provide tax breaks and other incentives for companies to innovate in various sectors of priority. Managers at UCB: Data is the New Drug case study have to assess whether their business can benefit from such government assistance and subsidies.

Consumer protection – Different countries have different consumer protection laws. Managers need to clarify not only the consumer protection laws in advance but also legal implications if the firm fails to meet any of them.

Political System & Stability, and its Impact on UCB: Data is the New Drug

Political System and Its Implications – Different political systems have different approach to free market and entrepreneurship. Managers need to assess these factors even before entering the market.

Freedom of Press is critical for fair trade and transparency. Countries where freedom of press is not prevalent there are high chances of both political and commercial corruption.

Corruption level – Ucb Analytics needs to assess the level of corruptions both at the official level and at the market level, even before entering a new market. To tackle the menace of corruption – a firm should have a clear SOP that provides managers at each level what to do when they encounter instances of either systematic corruption or bureaucrats looking to take bribes from the firm.

Independence of judiciary – It is critical for fair business practices. If a country doesn’t have independent judiciary then there is no point entry into such a country for business.

Government attitude towards trade unions – Different political systems and government have different attitude towards trade unions and collective bargaining. The firm needs to assess – its comfort dealing with the unions and regulations regarding unions in a given market or industry. If both are on the same page then it makes sense to enter, otherwise it doesn’t.

Economic Factors that Impact UCB: Data is the New Drug

Social Factors that Impact UCB: Data is the New Drug

Technological Factors that Impact UCB: Data is the New Drug

Environmental Factors that Impact UCB: Data is the New Drug

Legal Factors that Impact UCB: Data is the New Drug

Step 3 – Industry Specific Analysis

What is Porter Five Forces Analysis

PESTEL stands for political, economic, social, technological, environmental and legal factors that impact the external environment of firm in UCB: Data is the New Drug case study. PESTEL analysis of " UCB: Data is the New Drug" can help us understand why the organization is performing badly, what are the factors in the external environment that are impacting the performance of the organization, and how the organization can either manage or mitigate the impact of these external factors.

Step 4 – SWOT Analysis / Internal Environment Analysis

Step 5 – Porter Value Chain / VRIO / VRIN Analysis

Step 6 – Evaluating Alternatives & Recommendations

Step 7 – Basis for Recommendations

References :: UCB: Data is the New Drug case study solution